Qualitative and quantitative intravaginal targeting: Key to anti-HIV-1 microbicide delivery from test tube to In Vivo success

Journal of Pharmaceutical Sciences

Volumn 101, Issue 6, 2012, Pages 1950-1968

  Pillay, Viness ^a   Mashingaidze, Felix ^a   Choonara, Yahya E ^a   Du Toit, Lisa C ^a   Buchmann, Eckhart ^a   Maharaj, Vinesh ^b   Ndesendo, Valence M K ^c   Kumar, Pradeep ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^c ST JOHN'S UNIVERSITY OF TANZANIA   (Tanzania)

Author keywords

Macromolecular drug delivery; Mucosal delivery; Permeability; Pharmacokinetics pharmacodynamics; Physicochemical properties; Polymer biopolymer interactions; Polymeric drug delivery systems; Site specific delivery; Special populations; Targeted drug delivery

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD209 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DAPIVIRINE; ELVITEGRAVIR; ENFUVIRTIDE; GLYCOPROTEIN GP 120; MICROBICIDE; TENOFOVIR; TIFUVIRTIDE;

CD4+ T LYMPHOCYTE; CELL INTERACTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; MICROENVIRONMENT; PH; REVIEW; SEXUALLY TRANSMITTED DISEASE; VAGINA EPITHELIUM; VAGINA RING; VIRUS DETECTION; VIRUS ENTRY; VIRUS PARTICLE; VIRUS TRANSMISSION;

EID: 84859774242     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23098     Document Type: Review

References (149)

1. Ndesendo VMK, Pillay V, Choonara YE, Buchman E, Bayever DN, Meyer LCR. 2008. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS Pharm Sci Tech 9(2):505-520.
2. Hladik F, Doncel GF. 2010. Preventing mucosal HIV transmission with topical microbicides: Challenges and opportunities. Antiviral Res 88(S1):S3-S9.
3. Baleta A. 2007. A second chance for microbicides. Lancet 370(9581):17-18.
4. Hendrix CW, Cao YJ, Fuchs EJ. 2009. Topical microbicides to prevent HIV: Clinical drug development challenges. Annu Rev Pharmacol Toxicol 49:349-375.
5. Cutler B, Justman J. 2008. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis 8(11):685-697.
6. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996):1168-1174.
7. Mohammadi D. 2010. Trial results finally show potential for microbicidal HIV gel. Lancet Infect Dis 10(9):587.
8. AIDS Vaccine Advocacy Coalition. Ongoing clinical trials of topical microbicide candidates. Accessed July 25, 2011, at:.
9. International Partnership for Microbicides. IPM clinical trials Table II011. Accessed July 25, 2011, at:.
10. Microbicide Trial Network. Studies. Accessed February 14, 2011, at:.
11. Alliance for Microbicide Development. Pipeline update of microbicides and PrEP candidates. Accessed February 14, 2011, at:.
12. HIV Prevention Trials Network. HPTN study status table. Accessed February 14, 2011, at:.
13. Global Campaign for Microbicides. Current trials. Accessed February 14, 2011, at:.
14. AIDS Vaccine Advocacy Coalition. Microbicide trial results. Accessed July 14, 2011, at:.
15. AIDS Vaccine Advocacy Coalition. Ongoing and planned clinical trials of topical microbicide candidates. Accessed July 14, 2011, at:.
16. CONRAD. Cellulose sulphate Gel. Accesssed February 14, 2011, at:.
17. Microbicide Trial Network. Tenofovir gel provides high level of protection against HIV in rectal tissue. Accessed July 25, 2011, at:.
18. FHI. Cellulose sulphate ruled out as microbicide candidate. Accessed February 14, 2011, at:.
19. Horwood J. 2007. Cellulose sulphate trial halted. Lancet Infect Dis 7(3):183.
20. US National Institutes of Health. Clinical trials. Safety, tolerance and acceptability trial of the invisible Condom® in healthy women. Accessed July 25, 2011, at:.
21. Population Council. Projects. Clinical studies. Carraguard phase 3 clinical trial. Accessed February 14, 2011, at:.
22. Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, Cohen CR. 2009. Phase I dose-ranging safety trial of lactobacillus cripatus CTV-05 (LACTIN-V) for the prevention of bacterial vaginosis. Sex Transm Dis 36(9):564-569.
23. Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, Foster-Rosales A, Cohen CR. 2010. Phase 2a study assessing colonization efficiency, safety, and acceptability of lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis 37(12):745-750.
24. U.S. National Institutes of Health. Clinical trials. A study of the effects of advantage 24 on the rectum. Accessed July 25, 2011, at:.
25. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiègne-Traoré V, Uaheowitchai C, Karim SS, Mâsse B, Perriëns J, Laga M; COL-1492 Study Group. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 360(9338):971-977.
26. Van de Wijgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, Kumwenda N, Chirenje Z, Joshi S, Taha T, Padian N, Bollinger R, Nelson K. 2001. Phase I trial of the topical microbicide buffer gel: Safety results from four international sites. J AIDS 26(1):21-27.
27. Balzarini J, Van Damme L. 2007. Microbicide drug candidates to prevent HIV infection. Lancet 369(9563):787-789.
28. Perotti M, Pirovano A, Phillips DM. 2003. Carageenan formulation prevents macrophage trafficking from vagina: Implications for microbicide development. Biol Reprod 69(3):933-939.
29. Manson KH, Wyand MS, Miller C, Neurath AR. 2000. Effect of cellulose acetate phthalate topical cream on vaginal transmission of simian immunodeficiency virus in rhesus monkeys. Antimicrob Agents Chemother 44(11):3199-3302.
30. Anderson RA, Feathergill KA, Diao XH, Cooper MD, Kirkpatrick R, Herold BC, Doncel GF, Chany CJ, Waller DP, Rencher WF, Zaneveld LJ. 2002. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J Androl 23(3):426-438.
31. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang L, Nanda K, Rountree W. 2008. SAVVY vaginal gel (C31G) for prevention of HIV infection: A randomized controlled trial in Nigeria. PLoS One 3(1):e1474.
32. Tsai CC, Emau P, Jiang Y, Tian B, Morton WR, Gustafson KR, Boyd MR. 2003. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retrovir 19(7):535-541.
33. Balzarini J. 2005. Targeting the glycans of gp120: A novel approach aimed at the achilles heel of HIV. Lancet Infect Dis 5(11):726-731.
34. Smith M. 2006. TMC 120 vaginal ring promising as microbicides carrier. XVI International Conference; Toronto, Canada. August 13-18.
35. Thormar H, Bergsson G, Gunnarsson E, Georgsson G, Witvrouw M, Steingrímsson O, De Clercq E, Kristmundsdóttir T. 1999. Hydrogels containing monocaprin have potent microbicidal activities against sexually transmitted viruses and bacteria in vitro. Sex Transm Infect 75(3):181-185.
36. Mayer KH, Karim SA, Kelly C, Maslankowski L, Rees H, Profy AT, Day J, Welch J, Rosenberg Z; HIV Prevention Trials Network (HPTN) 020 Protocol Team. 2003. The safety and tolerability of PRO 2000 Gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 17(3):321-329.
37. Amarl E, Perdigao A, Souza MH, Mauck C, Waller D, Zaneveld L, Faúndes A. 2004. Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDIFORM) and a 2% nonoxynol-9 product. Contraception 70(6):492-497.
38. Garg S, Verman K, Anderson RA, Zaneveld LJ. 2004. Rapidly disintegrating novel bioadhesive vaginal tablets of polystyrene sulfonate (PSS), a potential microbicide formulation. 15th International Conference of AIDSBankok, Thailand, July 11-16, Abstract TuPeB4656.
39. Joshi SN, Katti U, Godbole S, Bharucha K, Kulkarni S, Risbud A, Mehendale S. 2005. Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfected women in Pune, India. Trans R Soc Trop Med Hyg 99(10):769-774.
40. Piret J, Lamontagne J, Bestman-Smith J, Roy S, Gourde P, Désormeaux A, Omar RF, Juhász J, Bergeron MG. 2000. In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses. J Clin Microbiol 38(1):110-119.
41. Jiang Y, Emau P, Cairns JS, Flanary L, Morton WR, McCarthy TD, Tsai CC. 2005. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV in macaques. AIDS Res Hum Retrovir 21(3):207-213.
42. D'Cruz OJ, Samuel P, Waurzyniak B, Uckun FM. 2003. In vivo evaluation of a gel formulation of stampidine, a novel non-spermicidal broad-spectrum anti-HIV microbicide. Am J Drug Deliv 1(4):275-285.
43. De Clercq E. 2006. The role of tenofovir in the prevention of HIV infections. AIDS 20(15):1990-1991.
44. D'Cruz OJ, Samuel P, Uckun FM. 2004. PHI-443: A novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide. Biol Reprod 71(6):2037-2047.
45. Kerr M. 2007. NNRTI shows safety as a topical anti-HIV microbicide in animal tests. Antimicrob Agents Chemother 51:1608-1615.
46. Hladick F, Hope TJ. 2009. HIV infection of the genital mucosa in women Curr HIV/AIDS Rep 6(1):20-28.
47. Haase AT. 2010. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464(7286):217-223.
48. Morrow G, Vachot L, Vagrnas P, Robbiani M. 2007. Current concepts of HIV transmission. Curr HIV AIDS Res 4(1):29-35.
49. Nazli A, Chan O, Dobson-Belair WN, Ouellet M, Tremblay MJ, Gray-Owen SD, Arsenault AL, Kaushic C. 2010. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog 6(4):e1000852.
50. Norvell MK, Berubi GI, Thompson RJ. 1984. Investigation of micro-trauma after sexual intercourse. J Reprod Med 29(4):269-271.
51. Gray RH, Wawer MJ. 2008. Reassessing the hypothesis on STI control for HIV prevention. Lancet 371(9630): 2064-2065.
52. Wilkinson E. 2007. Herpes treatment may limit HIV transmission and progression. Lancet Infect Dis 7(4):249.
53. Van de Perre P, Segondy M, Foulongne V, Ouedraogo A, Konate I, Huraux JM, Mayaud P, Nagot N. 2008. Herpes simplex virus and HIV-1: Deciphering viral synergy. Lancet Infect Dis 8(8):490-497.
54. Hayes RJ, Schulz KF, Plummer FA. 1995. The cofactor effect of genital ulcers in the per-exposure risk of HIV-1 transmission in sub-Saharan Africa. J Trop Hyg 98(1):108.
55. Hester R, Kennedy S. 2003. Candida infection as a risk factor for HIV-1 transmission. J Womens Health (Larchmt) 12(25):487-494.
56. Bomsel M. 1997. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 3(1):42-47.
57. Pignet V, Blauvelt A. 2002. Essential roles of dendritic cells in the pathogenesis and potential treatment of HIV disease. J Invest Dermatol 119(2):365-369.
58. Kawamura T, Kurtz SE, Blauvelt A, Shimada S. 2005. The role of Langerhans cells in the sexual transmission of HIV. J Dermatol Sci 40(3):147-155.
59. Wu L. 2008. Biology of HIV mucosal transmission. Curr Opin HIV AIDS 3(5):534-540.
60. Zaitseva M, Blauvelt A, Lee S, Lapham CK, Klaus-Kovtun V, Mostowski H, Manischewitz J, Golding H. 1997. Expression and function of CCR5 and CXCR4 on human langerhans cells and macrophages: Implications for HIV primary infection. Nat Med 3(12):1369-1375.
61. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM, Orenstein JM, Zimmerman PA, Blauvelt A. 2003. R5 HIV productively infects langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci USA 100(14):8401-8406.
62. Zhang Y, Moore JP. 1999. Will multiple co-receptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry. J Virol 73(4):3443-3448.
63. Wu L, KewalRamani VN. 2006. Dendritic-cell interactions with HIV: Infection and viral dissemination. Nat Rev Immunol 6(11):859-868.
64. Shen R, Richter HE, Smith PD. 2011. Early HIV-1 target cells in human vaginal and ectocervical mucosa. Am J Reprod Immunol 65(3):261-267.
65. Geijtenbeek TB, Know DS, Torensma R, van Vliet SJ, van Duijnhoven GCF, Middel J, Cornelissen ILMHA, Nottet SLW, KewalRamani VN, Littman D, Figdor CG, van Kooyk Y. 2000. DC-SIGN, a dendritic cell-surface HIV-1-binding protein that enhances trans-infection of T cells. Cell 100(5):587-597.
66. De Witte L, Nabatov A, Geijtenbeek TBH. 2007. Distinct roles for DC-SIGN-dendritic cells and Langerhans cells in HIV-1 transmission. Trends Mol Med 14(1):12-19.
67. Kwon DS, Gregorio G, Bittou N, Hendrickson WA, Littman DR. 2002. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T-cell infections. Immunity 16(1):135-144.
68. Donaghy H, Wilkinson J, Cunningham AL. 2006. HIV infection with dendritic cells: Has our focus been too narrow. J Leukoc Biol 80(5):1001-1012.
69. Blauvelt A, Asada H, Saville MN, Klaus-Kovtun V, Altman DJ, Yarchoan R. 1997. Productive infection of dentritic cells by HIV- and their ability to capture virus are mediated by separate pathways. J Clinical Invest 100(8):2043-2053.
70. Jenabian M, Saïdi H, Charpentier C, Bouhlal H, Schols D, Balzarini J, Bell TW, Vanham G, Bélec L. 2010. Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonisation. AIDS Res Ther 7:16.
71. Pope M, Haase A. 2003. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 9(7):847-852.
72. + T cells, epithelial apoptosis and a mucosal barrier defect. Gastroenterology 139(4):1289-13000.
73. Hladick F, McElrath MJ. 2008. Setting the stage: Host invasion by HIV. Nat Rev Immunol 8(6):447-457.
74. Hosein RR, Wilson DP. 2011. Incidence of HIV among men who have sex with men in France. Lancet Infect Dis 11(4):262-263.
75. Powers KA, Poole C, Pettifor AE, Cohen MS. 2008. Rethinking the heterosexual infectivity of HIV-1: A systematic review and meta-analysis. Lancet Infect Dis 8(9):553-63.
76. Sewankambo N, Gray RH, Wawer MJ, Paxton L, McNaim D, Wabwire-Mangen F, Serwadda D, Li C, Kiwanuka N, Hillier SL, Rabe L, Gaydos CA, Quinn TC, Konde-Lule J. 1997. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 350(9077):546-50.
77. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Casapia M, Ortiz A, Fuchs J, Buchbinder S, Koblin B, Zwerski S, Rose S, Wang J, Corey L; HPTN 039 Protocol Team. 2008. Effect of acyclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: A randomised, double-blind, placebo-controlled trial. Lancet 371(9630):2109-2119.
78. Templeton DJ. Male circumcision to reduce transmission of HIV. Curr Opin HIV AIDS 5(4):344-349.
79. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO. 2007. Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet 369(9562):643-656.
80. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, Sewankambo NK, Wabwire-Mangen F, Bacon MC, Williams CF, Opendi P, Reynolds SJ, Laeyendecker O, Quinn TC, Wawer MJ. 2007. Male circumcision for HIV prevention in men in Rakai, Uganda: A randomised trial. Lancet 369(9562):657-666.
81. Siegfried N, Muller M, Deeks J, Volmink J, Egger M, Low N, Walker S, Williamson P. 2005. HIV and male circumcision-A systematic review with assessment of the quality of studies. Lancet Infect Dis 5(3):165-173.
82. Denniston GC, Hill G. 2007. Male circumcision in HIV prevention. Lancet 369(9573):598.
83. Stone S. 2002. Microbicides: A new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov 1(12):977-985.
84. Barnhart KT, Izquiedo A, Pretorius ES, Shera DM, Shabbout M, Shannik A. 2006. Baseline dimensions of the human vagina. Hum Reprod 21(6):1618-1622.
85. Hu Q, Frank I, Williams V, Santos JJ, Watts P, Griffin GE, Moore JP, Pope M, Shattock RJ. 2004. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 199(8):1065-1075.
86. Pohlmann S, Baribaud F, Doms RW. 2001. DC-SIGN and DC-SIGNR: Helping hands for HIV. Trends Immunol 22(12):643-646.
87. Jameson B, Baribaud F, Pohlmann S, Ghavimi D, Mortari F, Doms RW, Iwasaki A. 2002. Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in human and rhesus macaques. J Virol 76(4):1866-1875.
88. Gummuluru S, Rogel M, Stamatatos L, Emerman M. 2003. Binding of human immunodeficiency virus type 1 to immature dendritic cells can occur independently of DC-SIGN and mannose binding C-type receptors via a cholesterol-dependent pathway. J Virol 77(23):12865-12874.
89. Turvile SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, Miranda-Saksena M, Dable J, Stössel H, Romani N, Piatak M Jr, Lifson JD, Pope M, Cunningham AL. 2004. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 103(6):2170-2179.
90. Lamers SL, Salemi M, McGrath MS, Fogel GB. 2008. Prediction of R5, X4 and R5×4 HIV-1 co-receptor usage with evolved neural networks. IEEE/ACM Trans Comput Biol Bioinform 5(2):291-300.
91. Shattock R, Solomon S. 2004. Microbicides-Aids to safer sex. Lancet 363(9414):1002-1003.
92. Du Toit LC, Pillay V, Choonara YE. 2009. Nano-microbicides: Challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS. Adv Drug Deliv Rev. 62(4-5):532-546.
93. Elechiguerra J, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ. 2005. Interaction of silver nanoparticles with HIV-1. Nanobiotechnology 3(6):1-10.
94. Yacaman MJ, Elechiquerra JL, Lara HH, Burt JL. 2006. Protein-Noble metal nano-particles. World Intellectual Property Organization Patent WO-06/053325.
95. Witvrow M, Fikkert V, Pluymers W, Matthews B, Mardel K, Schols D, Raff J, Debyser Z, De Clercq E, Holan G, Pannecouque C. 2000. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Mol Pharmacol 58(5):1100-1108.
96. McCarthy TD, Karellas P, Henderson SA, Giannis M, O'Keefe DF, Heery G, Paull JR, Matthews BR, Holan G. 2005. Dentrimers as drugs, discovery and preclinical and clinical development of dentrimer-based microbicides for HIV and STI prevention. Mol Phamacol 2(4):312-318.
97. Marcorin GL, Da Ros T, Castellano S. 2000. Design and synthesis of novel [60] fullerene derivatives as potential HIV aspartic protease inhibitors. Org Lett 2(25):3955-3958.
98. Schuon A. 2008. Positive initial results pave the way for definitive follow-up studies. Anti-HIV nanoviricide drug candidate demonstrate significant therapeutic efficacy in animal trails. Nanotechnology Now. Accessed February 14, 2011, at:.
99. Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F. 2007. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 129(2):263-275.
100. Hilber AM, Chersich MF, Van de Wijgert JHHM, Rees H, Temmerman M. 2007. Vaginal practices, microbicides and HIV: What do we need to know? Sex Transm Infect 83(7):505-507.
101. Lai SK, Hida K, Shukair S, Wang YY, Figueiredo A, Cone R, Hope TJ, Hanes J. 2009. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol 83(21):11196-11200.
102. Brzezinski, A., Stern, T., Arbel, R., Rahav, G., Benita, S. 2004. Efficacy of a novel pH-buffering tampon in preserving the acidic vaginal pH during menstruation. Int J Gynaecol Obstet 85(3):298-300.
103. Von Mollendorf CE, Van Damme L, Moyes JA, Rees VH, Callahan MM, Mauck CK, Puren AJ, Tweedy K, Taylor D. 2010. Results of a safety and feasibility study of the diaphragm used with ACIDFORM gel or KY jelly. Contraception 81(3):232-239.
104. Hemmerling A, Potts M, Walsh J, Young-Holt B, Stefanski DA. 2007. Lime juice as a candidate microbicide? An open-label safety trial of 10% and 20% lime juice used vaginally. J Women Health 16(7): 1041-1051.
105. Kozlowski PA, Neutra MR. 2003. The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med 3(3):217-228.
106. Bergmeier LA, Lehner T. 2006. Innate and adaptive mucosal immunity in protection against HIV infection. Adv Dent Res 19(1):21-28.
107. Bai L, Zhang Z, Zang H, Li X, Yu Q, Lin H, Yang W. 2008. HIV-1 Tat protein alter the tight junction integrity and function of pigment epithelium: An in vitro study. BMC Infect Dis 8:77.
108. Geonnotti AR, Katz DF. 2006. Dynamics of HIV neutralization by a microbicide formulation layer: Biophysical fundamentals and transport theory. Biophys J 91(6):2121-2130.
109. Fukunag T, Sasaki M, Araki K, Okamoto T, Yasuoka T, Tsujikawa T, Fujiyama Y, Bamba T. 2003. Effects of the soluble fibre pectin on intestinal cell proliferation, fecal short chain fatty acid production and microbial population. Digestion 67(1-2):42-49.
110. Woolfson AD, Umrethia ML, Kett VL, Malcolm RK. 2010. Freeze-dried, mucoadhesive system for vaginal delivery of the HIV microbicide dapivarine: Optimization by an artificial neural network. Int J Parm 388(1-2):136-143.
111. Valenta C. 2005. The use of mucoadhesive polymers in vaginal delivery. Adv Drug Del Rev 57(11):1692-1712.
112. Ndesendo VMK, Pillay V, Choonara YE, du Toit LC, Buchmann E, Meyer LC, Khan RA, Rosin U. 2010. Investigation of the physicochemical and physicomechanical properties of a novel intravaginal bioadhesive polymeric device in the pig model. AAPS Pharm Sci Tech 11(2):793-808.
113. Thomas JA, Ott DE, Gorelick RJ. 2007. Efficiency of human immunodeficiency virus type 1 postentry infection process: Evidence against disproportionate numbers of defective virions. J Virol 81(8): 4367-4370.
114. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, Lutalo T, Li X, vanCott T, Quinn TC; Rakai Project Team. 2001. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357(9263):1149-53.
115. Zhang L, He T, Talal A, Wang G, Frankel SS, Ho DD. 1998. Distribution of human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5. J Virol 72(6):5035-5045.
116. Zoeteweij JP, Blauvelt A. 1998. HIV-dendritic cell interactions promote efficient viral infection of T cells. J Biomed Sci 5(4):253-259.
117. Miller CJ, Shattock RJ. 2003. Target cells in vaginal HIV transmission. Micro Infect 5(1): 59-67.
118. Cunningham AL, Harman AN, Donaghy H. 2007. DC-SIGN 'AIDS' HIV immune evasion and infection. Nat Immunol 8(6):556-558.
119. Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, Tressler R, Worsley J, Kashuba AD. 2009. Maraviroc concentrates in cervicovaginal fluid and vaginal tissue of HIV-1 negative women. J Acquir Immune Defic Syndr 51(5):546-553.
120. Kennedy EM, Gavegnano C, Nguyeu L, Slater R, Lucas A, Fromentin E, Schinazi RF, Kim B. 2010. Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages. J Biol Chem 285(50):39380-39391.
121. Alliance for Microbicides Development. Microbicide candidates in pre-clinical development as of Feb, 2007. Combinations. Accessed July 25, 2011, at:.
122. Liu S, Lu H, Neurath R, Jiang S. 2005. Combination microbicides cellulose acetate 1, 2 benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1. Antimicrob Agen Chemother 49(5):1830-1836.
123. Sexton A, Harman S, Shattock RJ, Ma K-C. 2009. Design, expression, and characterization of a multivalent, combination HIV microbicide. FASEB J 23(10):3590-3600.
124. D'Cruz OJ, Uckun FM. 2007. Preclinical evaluation of a dual-acting microbicidal prodrug WHI-07 in combination with vanadocene dithiocarbomate in the female reproductive tract of rabbit, pig and cat. Toxicol Pathol 35(7):910-927.
125. Miller CJ, Alexander NJ, Sutjipo S, Lackner AA, Gettie A, Hendrickx AG, Lowenstine LJ, Jennings M, Marx PA. 1989. Genital mucosal transmission of simian immunodeficiency virus: Animal model for heterosexual transmission of human immumodeficiency virus. J Virol 63(10):4277-4284.
126. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, La Franco-Scheuch L, Compton L, Duan L, Shore MD, Zupancic M, Busch M, Carlis J, Wolinsky S, Haase AT. 2005. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 79(14):9217-9227.
127. Lukashov VV, Goudsmit J. 1997. Founder virus population related to route of virus transmission: A determination of intrahost human immunodeficiency virus type 1 evolution? J Virol 71(3):2023-2030.
128. Haase AT. 2005. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 5(10):783-792.
129. Richman DD, Wrin T, Little SJ, Petropoulos CJ. 2003. Rapid evolution of the neutralizing antibody response to HIV-1 type infection. Proc Natl Acad Sci USA 100(7):4144-4149.
130. Lacey CJN, Wright A, Weber JN, Profy AT. 2006. Direct measurement of in-vivo vaginal microbicide levels of Pro2000 achieved in a human safety study. AIDS 20(7):1027-1039.
131. Vernazza PL, Gillian BL, Dyer J, Fiscus SA, Eron JJ, Frank AC, Cohen MS. 1997. Quantification of HIV in semen: Correlation with antiviral treatment and immune status. AIDS 11(8):987-993.
132. Tachet A, Dulioust E, Salmon D, De Almeida M, Rivalland S, Finkielsztejn L, Heard I, Jouannet P, Sicard D, Rouzioux C. 1999. Detection and quantification of HIV-1 in semen: Identification of subpopulation of men at high potential risk of viral sexual transmission. AIDS 13(7):823-831.
133. Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR. 2006. Vaginal microbicides: Detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis 6:90.
134. Gupta KM. 2008. Novel technologies for vaginal delivery of microbicides. Ph.D. Thesis. The University of Utah.
135. Chan DC, Kim PS. 1998. HIV entry and its inhibition. Cell 93(5):681-684.
136. Zhu P, Liu J, Bess J Jr, Chertova E, Lifson JD, Grisé H, Ofek GA, Taylor KA, Roux KH. 2006. Distribution and three-dimensional structure of HIV virus envelope spikes. Nature 441(7095):847-852.
137. Zhu P, Chertova B Jr, Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH. 2003. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virons. Proc Natl Acad Sci USA 100(26):15812-15817.
138. Poignard P, Saphire EO, Parren PW, Burton DR. 2001. gp120: Biologic aspects of structural features. Annu Rev Immunol 19:253-274.
139. Chan DC, Fass D, Berger JM, Kim PS. 1997. Core structures of Gp41 from the HIV envelop glycoprotein. Cell 89(2):263-273.
140. Yang X, Kurteva S, Ren X, Lee S, Sodroski J. 2005. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type1. J Virol 79(19):12132-12147.
141. Yang X, Kurteva S, Ren X, Lee S, Sodroski J. 2006. Subunit stiochiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into cells. J Virol 80(9):4388-4395.
142. Magnus C, Rusert P, Bonhoeffer S, Trkola A, Regoes RR. 2009. Estimating the stoichiometry of human immunodeficiency virus entry. J Virol 83(3):1523-1531.
143. Magnus C, Regoes RR. 2010. Estimating the stoichiometry of HIV neutralization. PLOS Comp Biol 6(3):e1000713.
144. Klaase PJ. 2007. Modeling how many envelope glycoprotein trimers per viron particle in human immunodeficiency virus infectivity and its neutralization by antibody. Virology 369(2):245-262.
145. O'keefe BR, Shenoy SR, Xie D, Zhang W, Muschik JM, Currens MJ, Chaiken I, Boyd MR. 2000. Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoprotein gp120 and gp41. Mol Pharmacol 58(5):982-992.
146. Lao LL, Venkatraman SS, Peppas NA. 2008. Modeling of drug release from biodegradable polymer blends. Eur J Pharm Biopharm 70(3):796-803.
147. Heller J, Barr J, Ng SY, Abdellauoi KS, Gurny R. 2002. Poly (ortho esters): Synthesis, characterization, properties and uses. Adv Drug Deliv Rev 54(7):1015-1039.
148. Lai SK, Wang Y, Hanes J. 2009. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Del Rev 61(2):158-171.
149. World Health Organization. International HIV data. Accessed February 15, 2011, at:.